Stock Ratings / Health Care / CLOV / earnings

FTRE (35) ACHC (37) CELC (36) PSNL (36) ⌘ Pro Terminal →

Clover Health Investments Corp. (Class A) (CLOV) Next Earnings Date & Expected ±10.6% Move

$4.58 -4.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Clover Health Investments Corp. (Class A) (CLOV) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.43B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLOV)Realized 20D OHLCV Swing Band: ±10.6%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±10.6% Swing Band

±$0.49 Expected Swing

MODEL EARNINGS SETUP GAUGE

CLOV Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: 40.3%

Model Bullish Setup (30/100)Model Risk Weight (70/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$1.92B	-$85.5M	-$69.0M	52%
FY 2024	2024-12-31	$1.37B	-$43.0M	$33.3M	52%
FY 2023	2023-12-31	$1.26B	-$213.4M	-$144.7M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLOV)

✓Walkthrough of CLOV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLOV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +66.55%▲ ASCENDING TRIANGLE

2026-10-30O $4.53H $4.58L $4.34C $4.58VOL 4.65M

RES: $5.22SUP: $4.17SMA50: $4.51SMA200: $3.54

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLOV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLOV Butterfly Map → + Track CLOV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +40.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLOV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLOV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLOV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLOV)

Health Care Rank #939 of 1016 ⚔️ FTRE vs CLOV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLOV vs. FTRE, ACHC, CELC, PSNL)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Clover Health Investments Corp. (Class A) (CLOV) ranks #939 by composite RQD confidence (30/100, grade E) and #224 by equity capitalization ($2.43B). Within this direct 5-issuer industry benchmark cohort, CLOV leads on earnings valuation at N/A trailing P/E, while ACHC leads on capital efficiency and profitability with -24.8% ROIC and — gross margin. ACHC currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with CLOV at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLOV ACTIVE Clover Health Investments Corp. (Class A)	E	30/100	—	—	-29.3%	-4.38%	$2.43B	Benchmark Subject
FTRE Fortrea Holdings Inc.	D-	35/100	—	—	-35.0%	-10.61%	$2.20B	/ftre-vs-clov →
ACHC Acadia Healthcare Company Inc.	D-	37/100	—	—	-24.8%	-0.17%	$2.74B	/achc-vs-clov →
CELC Celcuity Inc.	D-	36/100	—	—	-35.0%	-0.23%	$3.39B	/celc-vs-clov →
PSNL Personalis Inc.	D-	36/100	—	22.7%	-35.0%	-0.47%	$1.70B	/psnl-vs-clov →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001801170

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Clover Health Investments Corp. (Class A) (CLOV) reported GAAP revenue of $1.92B (+40.3% vs. FY2024 revenue of $1.37B , and +52.7% cumulative change since FY2023) , GAAP net income of -$85.5M, operating cash flow of -$66.9M, and free cash flow of -$69.0M (-307.2% YoY). On the balance sheet, CLOV closed FY2025 with $541.0M in total assets against $0 in total debt (Altman Z-Score: 3.62, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.92B	-$85.5M	-$66.9M	-$69.0M	$541.0M	—
FY2024 (FY)	2024-12-31	$1.37B	-$43.0M	$34.8M	$33.3M	$580.7M	—
FY2023 (FY)	2023-12-31	$1.26B	-$213.4M	-$144.7M	-$144.7M	—	—

3. CLOV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Clover Health Investments Corp. (Class A) (NASDAQ: CLOV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $4.58 (-4.38% 1D, market cap $2.43B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLOV ranks #939 in composite RQD confidence.

How does CLOV compare to FTRE and ACHC in the Health Care sector?

Within the Health Care sector (Medical Specialities), CLOV carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -29.3%. By comparison, FTRE (Fortrea Holdings Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B) and ACHC (Acadia Healthcare Company Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -24.8%, cap $2.74B). Among the 5-stock peer group, CLOV leads on earnings multiple (N/A) while ACHC leads on capital efficiency (-24.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLOV?

Per CLOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001801170), Clover Health Investments Corp. (Class A) generated $1.92B in revenue (+40.3% YoY), -$85.5M in net income, and -$69.0M in free cash flow against $541.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLOV trading relative to its 50-day, 200-day, and 52-week technical levels?

CLOV last traded at $4.58 (-4.38% on volume of 4,070,913 shares), positioning the stock +1.55% above its 50-day simple moving average ($4.51) and +29.38% above its 200-day simple moving average ($3.54). Across its 52-week range of $1.58 to $5.59, CLOV sits at the 74.8% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($4.09 to $5.07).

CLOV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is CLOV's next earnings date?

Based on SEC filing cadence, Clover Health Investments Corp. (Class A) (CLOV)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CLOV stock expected to move on earnings?

Volatility modeling currently projects a ±10.6% event move for CLOV, spanning a range between $4.09 and $5.07.

Direct Sub-Reports: CLOV RQD Cockpit CLOV 12M Forecast CLOV Earnings & Move CLOV Dividends & DRIP CLOV Insiders & 13F CLOV Whale Options CLOV Profit Sankey CLOV News & Why